Study of MK-8690 for moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had ulcerative colitis for at least 3 months.
- Your UC must be moderate to severe in activity.
- You must weigh at least 40 kg (about 88 pounds).
- You must have tried other treatments for UC and they didn't work well, stopped working, or caused problems.
- You cannot have Crohn's disease or other types of colitis.
- You cannot have had your colon removed or a colostomy/ileostomy.
- You must not have active infections like hepatitis B, C, HIV, or tuberculosis.
- You cannot have a history of cancer (except certain skin cancers) within the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
This trial tests a new drug called SAR442970 for adults with moderate to severe ulcerative colitis (UC) that has not responded well to standard treatments or other advanced therapies. The goal is to see if it can reduce symptoms and improve quality of life.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
This study tests an investigational drug for people with active mild-to-moderate ulcerative colitis. It aims to see if the drug can improve symptoms without needing advanced treatments like biologics.
This trial studies whether an oral treatment called MS-20 can improve ulcerative colitis (UC) in adults with moderate to severe disease. You may be asked to provide stool samples from home and avoid certain foods and medicines before screening and during the study.
This study tests several new treatments to see if they are safe and helpful for people with moderate to severe ulcerative colitis. If you have not responded well to standard treatments, this might be an option.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.